Chinese Journal of Pharmacovigilance ›› 2023, Vol. 20 ›› Issue (8): 956-960.
DOI: 10.19803/j.1672-8629.20220611
LI Yamei1, SHUI Rong2
Received:
2022-10-20
Online:
2023-08-15
Published:
2023-08-07
CLC Number:
LI Yamei, SHUI Rong. Research progress in tofacitinib for juvenile idiopathic arthritis[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 956-960.
[1] MARTINI A, RAVELLI A, AVCIN T, et al.Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus[J]. J Rheumatol, 2019, 46(2): 190-197. [2] CAIFENG L, SHIPENG L.Precise diagnosis and treatment of juvenile idiopathic arthritis[J]. Chin J Practical Pediatrics(中国实用儿科杂志), 2021, 36(1): 1-5. [3] HORTON DB, SHENOI S.Review of environmental factors and juvenile idiopathic arthritis[J]. Open Access Rheumatol, 2019, 11: 253-267. [4] MOURA RA, FONSECA JE.B cells on the stage of inflammation in juvenile idiopathic arthritis: leading or supporting actors in disease pathogenesis?[J]. Front Med (Lausanne), 2022, 9(4): 851532. [5] RIGANTE D, BOSCO A, ESPOSITO S.The etiology of juvenile idiopathic arthritis[J]. Clin Rev Allergy Immunol, 2015, 49(2): 253-261. [6] FRAGOULIS GE, MCINNES IB, SIEBERT S.JAK-inhibitors. new players in the field of immune-mediated diseases, beyond rheumatoid arthritis[J]. Rheumatology (Oxford), 2019, 58(Suppl 1): i43-i54. [7] COBB JE, ANNE H, WENDY T.The genetics of juvenile idiopathic arthritis: current understanding and future prospects[J]. Rheumatology(Oxford), 2014, 53(4): 592-599. [8] VEIT TD, VIANNA P, SCHEIBEL I, et al.Association of the HLA-G 14-bp insertion/deletion polymorphism with juvenile idiopathic arthritis and rheumatoid arthritis[J]. Tissue Antigens, 2008, 71(5): 440-446. [9] PRAHALAD S, GLASS DN.A comprehensive review of the genetics of juvenile idiopathic arthritis P[J]. Pediatric Rheumatology Online Journal, 2008, 6(1): 11. [10] THOMSON W, BARRETT JH, DONN R, et al.Juvenile idiopathic arthritis classified by the ILAR criteria: HLA associations in UK patients[J]. Rheumatology(Oxford), 2002, 41(10): 1183-1189. [11] CRISPINO N, CICCIA F.JAK/STAT pathway and nociceptive cytokine signaling in rheumatoid arthritis and psoriatic arthritis[J]. Clin Exp Rheumatol, 2021, 39(3): 668-675. [12] HAMMARÉN HM, VIRTANEN AT, RAIVOLA J, et al. The regulation of JAKs in cytokine signaling and its breakdown in disease[J]. Cytokine, 2019, 118: 48-63. [13] ZHOU SH, XIONG YQ, CHEN Y.Recent research on tofacitinib in the treatment of pediatric rheumatic diseases[J]. Zhongguo Dang Dai Er Ke Za Zhi, 2022, 24(4): 447-453. [14] MURRAY GM, RENTON WD.Tofacitinib for juvenile idiopathic arthritis[J]. Lancet, 2022, 399(10338): 1865-1866. [15] YAN Q, CHEN WW, SONG H, et al.Tofacitinib ameliorates lupus through suppression of T cell activation mediated by TGF-Beta type I receptor[J]. Frontiers in Immunology, 2021, 12(7): 675542. [16] OGILVIE EM, SAMUEL JM, WOO P.Gene expression in active systemic JIA after anti-IL1 and anti-IL6R treatment[J]. Pediatr Rheumatol Online J, 2008, 6(Suppl 1): 28. [17] CANNY S, MELLINS E.New frontiers in the treatment of systemic juvenile idiopathic arthritis[J]. F1000Res, 2017, 6: 971. [18] RUPERTO N, BRUNNER HI, ZUBER Z, et al.Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study[J]. Pediatr Rheumatol Online J, 2017,15(1):86. [19] YU B, WANG X, YANG Y, et al.Evaluation of tofacitinib citrate bioequivalence based on pharmacokinetic parameters in healthy Chinese subjects[J]. Int J Clin Pharmacol Ther, 2021, 59(4): 343-352. [20] DOWTY ME, LIN J, RYDER TF, et al.The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans[J]. Drug Metab Dispos, 2014, 42(4): 759-773. [21] Rheumatology Group, Pediatrics Branch of Chinese Medical Association, Rheumatology Group of the Chinese Physicians' Association of Rheumatology and Immunology, Cross-Straits Medical and Health Exchange Association, Rheumatology and Immunology Committee, Pediatrics Group, et al. Expert consensus on biologics and small molecule targeted drug therapy for juvenile idiopathic arthritis (2022 edition)[J]. Chinese Journal of Practical Pediatrics(中国实用儿科杂志), 2022, 37(14): 1066-1073. [22] HUANG ZX, LEE PY, YAO XY, et al.Tofacitinib treatment of refractory systemic juvenile idiopathic arthritis[J]. Pediatrics, 2019, 143(5): e20182845. [23] KOSTIK MM, RAUPOV RK, SUSPITSIN EN, et al.The safety and efficacy of tofacitinib in 24 cases of pediatric rheumatic diseases: single centre experience[J]. Frontiers in Pediatrics, 2022, 10: 820586. [24] VILLACIS-NUNEZ DS, BILCHA K, SPRAKER M, et al.Severe immediate and delayed hypersensitivity reactions to biologics in a toddler with systemic juvenile idiopathic arthritis[J]. Journal of Investigative Medicine High Impact Case Reports, 2022, 10: 1-6. [25] BAUERMANN P, HEILIGENHAUS A, HEINZ C.Effect of janus kinase inhibitor treatment on anterior uveitis and associated macular edema in an adult patient with juvenile idiopathic arthritis[J]. Ocular Immunology and Inflammation, 2019, 27(8): 1232-1234. [26] BING SJ, LYU C, XU B, et al.Tofacitinib inhibits the development of experimental autoimmune uveitis and reduces the proportions of Th1 but not of Th17 cells[J]. Molecular Vision, 2020, 26: 641-651. [27] RUPERTO N, BRUNNER HI, SYNOVERSKA O, et al.Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial[J]. Lancet, 2021, 398(10315): 1984-1996. [28] VUKIĆ V, SMAJO A, VIDOVIĆ M, et al.Beyond the guidelines management of juvenile idiopathic arthritis: a case report of a girl with polyarticular disease refractory to multiple treatment options and Leri Weill syndrome[J]. BMC Pediatrics, 2021, 21(1): 40. [29] GUZMAN J, OEN K, TUCKER LB, et al.The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort[J]. Ann Rheum Dis, 2015, 74(10): 1854-1860. [30] ASCHENBRENNER DS.Tofacitinib trial prompts FDA review of adverse effects[J]. American Journal of Nursing, 2019, 119(6): 25. [31] HAWERKAMP HC, DOMDEY A, RADAU L, et al.Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation[J]. Arthritis Research & Therapy, 2021, 23(1): 144. [32] SHIBATA T, MUTO J, HIRANO Y, et al.Palmoplantar pustulosis-like eruption following tofacitinib therapy for juvenile idiopathic arthritis[J]. JAAD Case Rep, 2019, 5(6): 518-521. [33] ZHONG LQ, SONG HM.Interpretation on the 2021 American college of rheumatology guideline for the treatment of juvenile idiopathic arthritis[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 992-998. [34] ZAND MS.Tofacitinab in renal transplantation[J]. Transplant Rev (Orlando), 2013, 27(3): 85-89. [35] KHOSROW-KHAVAR F, KIM SC, LEE H, et al.Tofacitinib and risk of cardiovascular outcomes: results from the Safety of tofacitinib in routine care patients with rheumatoid arthritis (STAR-RA) study[J]. Ann Rheum Dis, 2022, 81(6): 798-804. [36] SANDBORN WJ, LAWENDY N, DANESE S, et al.Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment[J]. Aliment Pharmacol Ther, 2022, 55(4): 464-478. |
[1] | LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932. |
[2] | WANG Yinghe, LI Mingqi, ZHAO Xiaolu, MA Yuehong. Different Functions of Autophagy in Diseased Livers [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 956-960. |
[3] | WANG Chunting, CHEN Yafei. Considerations for Revision of Safety Information in the Post-Marketing Instructions of Chemical Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 776-779. |
[4] | ZHU Huijuan, REN Jingtian. Safety Risks of Human Rabies Immunoglobulin [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 786-789. |
[5] | LIU Yiyu, LI Yanwen, WANG Jiao, ZHOU Wenjing, PENG Yumeng, HE Wenbin, LI Zhiyong. Efficacy Semantic Mining and Safety Analysis of Chinese Patent Medicines for Headache [J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 674-679. |
[6] | ZHANG Huiting, LI Youlin, LI Lei, YAN Yue, YAO Ting, LI Chunlei, SHI Qi. Toxicity of Single-Dose and Repeated-Dose Administration of Guisha Zichuan Granules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 547-553. |
[7] | DI Ruiyi, XU Lu, YANG Jingfan, ZHU Lili, XUE Shujuan, CHEN Suiqing, SUN Xiaoya. Morphology, Chemical Composition and Safety of Three Toxic Traditional Chinese Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 560-563. |
[8] | FAN Liping, LU Shu, SUN Huiyuan. Efficacy and Safety of Panax Quinquefolium Saponin in Adjuvant Treatment of Angina Pectoris of Coronary Heart Disease: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 570-574. |
[9] | WANG Fengxin, LI Lei, HUANG Xurui, ZHAO Yun, LING Ruby, YANG Yang, LIANG Changhao, ZENG Yuntao, ZHENG Yingjun, TANG Yuanchen, LIU Jiatao, WANG Chengxiang, WEN Tiancai, LI Ping. Efficacy and Safety of Danshen Decoction in Treatment of Coronary Heart Disease [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 575-579. |
[10] | WU Shiqi, SU Su, YAN Suying, ZHANG Qingxia. Bleeding Induced by Rivaroxaban Combined with PK-DDI in Patients with Nonvalvular Atrial Fibrillation and Renal Insufficiency:a Retrospective Cohort Study [J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 415-419. |
[11] | ZHANG Yunhui, CHEN Haoyun, ZHONG Luhua, FANG Caifu, HUANG Huanjun, GUO Chenchen, DONG Xinyi, SHI Feng, LIANG Weiting. 159 Cases of Adverse Reactions to Immune Checkpoint Inhibitors [J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 442-446. |
[12] | LUO Wen, WU Jing, HE Dake, YANG Rui. One Case of Dermatitis Medicamentosa in a Paediatric Epilepsy Patient Caused by Lacosamide Oral Solution [J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 452-455. |
[13] | GUO Dongqi, WANG Hao, BAI Xin, BAI Jianqi, SU Hongmei, ZHANG Jingru, GUO Xiaofei, ZHAO Xiaoqi, WANG Min, WANG Yuan, ZHANG Ping. Identification of Druggable Targets for Intervertebral Disc Degeneration Based on Multi-Omics Data-Driven Mendelian Randomization and Prediction of Traditional Chinese Medicine Interventions [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 241-248. |
[14] | KANG Jiaqi, GUO Xiaofei, SU Hongmei, BAI Jianqi, ZHU Hongwei, BAI Xin, CHEN Xin, WANG Hao, ZHAO Xiaoqi, GUO Dongqi, WANG Yuan, ZHANG Ping. Interventions of Bushen Huoxue Decoction in Lumbar Intervertebral Disc Degeneration of Kidney Deficiency and Blood Stasis Type in Rats [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 249-257. |
[15] | BU Zixuan, XUE Mengwei, TIAN Jiawei, KE Kaile, WANG Ziying, LI Xiao, LU Tiangong. Interventions of Guizhi Fuling Pills in Properties of Ovarian Cancer Stem Cells [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 263-270. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||